Journal of Nutrition,Fasting and Health

Journal of Nutrition,Fasting and Health

The Effect of Resveratrol with Interval Training on Oxidative Stress Biomarkers and Liver Enzymes in Men with Non-Alcoholic Fatty Liver Disease

Document Type : Research Paper

Authors
Farhad Nikouseresht
Zaher Etemad
Khalid Mohammadzadehsalamat
Department of Physical Education and Sport Sciences, Sa.C., Islamic Azad University, Sanandaj, Iran.
10.22038/jnfh.2026.91852.1602
Abstract
Introduction: As resveratrol and exercise may influence oxidative stress processes in non-alcoholic fatty liver disease (NAFLD), the present study aimed to investigate the effects of interval training combined with resveratrol supplementation on liver enzymes, total antioxidant capacity (TAC), and malondialdehyde (MDA) in individuals with NAFLD. Methods: Forty-eight participants were randomly assigned to four groups, with 12 participants in each group: 1) resveratrol, 2) training, 3) training plus resveratrol, and 4) placebo. The exercise intervention was performed for eight weeks, three sessions per week. Participants in the resveratrol and training plus resveratrol groups received one 400 mg resveratrol capsule daily for eight weeks. The placebo group received one 400 mg starch capsule daily for the same duration. Liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as TAC and MDA levels, were assessed at pre-test and post-test. Two-way ANOVA and paired-samples t-tests were used for statistical analysis, with the significance level set at P ≤ 0.05. Results: Resveratrol supplementation significantly increased TAC (P = 0.002) and decreased ALT levels (P = 0.01). In addition, training significantly reduced ALT levels (P = 0.001). Conclusion: The findings suggest that resveratrol supplementation and interval training alone may improve some NAFLD-related outcomes by improving liver enzyme status. However, their combination did not appear to exert synergistic effects.
Keywords
Non-alcoholic fatty liver disease
Resveratrol
Training
Oxidative stress
Subjects
1.                Younossi ZM. Non-alcoholic fatty liver disease–a global public health perspective. J Hepatol. 2019;70(3):531–44.
2.                Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801.
3.                Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. lancet Gastroenterol Hepatol. 2023;8(1):20–30.
4.                Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–64.
5.                Younossi ZM. current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28(1):2–12.
6.                Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434–41.
7.                Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–64.
8.                Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem. 2010;43(10–11):815–21.
9.                Li S, Tan H-Y, Wang N, Zhang Z-J, Lao L, Wong C-W, et al. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 2015;16(11):26087–124.
10.              Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol WJG. 2014;20(23):7366.
11.              Pandey KB, Rizvi SI. Anti-oxidative action of resveratrol: Implications for human health. Arab J Chem. 2011;4(3):293–8.
12.              Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012;107(2):202–10.
13.              Franco JG, Lisboa PC, Lima NS, Amaral TAS, Peixoto-Silva N, Resende AC, et al. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J Nutr Biochem. 2013;24(6):960–6.
14.              De La Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans. 2007;35(5):1156–60.
15.              Zhu W, Chen S, Li Z, Zhao X, Li W, Sun Y, et al. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutr Metab (Lond). 2014;11(1):35.
16.              Kavas GÖ, Ayral PA, Elhan AH. The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats. Adv Clin Exp Med. 2013;22(1):151–5.
17.              Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–43.
18.              Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients  with non-alcoholic fatty liver disease: a randomized controlled trial. Dig liver Dis  Off J Ital Soc  Gastroenterol Ital Assoc Study Liver. 2015 Mar;47(3):226–32.
19.              Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51(4):456–64.
20.              Asghari S, Rafraf M, Farzin L, Asghari-Jafarabadi M, Ghavami S-M, Somi M-H. Effects of pharmacologic dose of resveratrol supplementation on oxidative/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial. Adv Pharm Bull. 2018;8(2):307.
21.              Davari F, Alimanesh Z, Alimanesh Z, Salehi O, Hosseini SA. Effect of training and crocin supplementation on mitochondrial biogenesis and redox-sensitive transcription factors in liver tissue of type 2 diabetic rats. Arch Physiol Biochem. 2022;128(5):1215–20.
22.              Park S-Y, Kwak Y-S, Park S-Y, Kwak Y-S. Impact of aerobic and anaerobic exercise training on oxidative stress and antioxidant defense in athletes. J Exerc Rehabil. 2016;12(2):113–7.
23.              Shamsoddini A, Sobhani V, Chehreh MEG, Alavian SM, Zaree A. Effect of aerobic and resistance exercise training on liver enzymes and hepatic fat in Iranian men with nonalcoholic fatty liver disease. Hepat Mon. 2015;15(10):e31434.
24.              Chicco AJ, Hydock DS, Schneider CM, Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006;100(2):519–27.
25.              Arammi S, Sahragard M, Seyed A, Salehi O, Hosseini SA, Mosallanezhad Z. The effects of swimming training at different temperatures along with cinnamon supplementation on liver enzymes and thyroid hormones in diabetic rats. Avicenna J Phytomedicine. 2024;14(1).
26.              Weston M, Taylor KL, Batterham AM, Hopkins WG. Effects of low-volume high-intensity interval training (HIT) on fitness in adults: a meta-analysis of controlled and non-controlled trials. Sport Med. 2014;44(7):1005–17.
27.              Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. 2011; 1334-59.
28.              Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and  validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381–95.
29.              Wang GH, Ruan L, Wu RP, Jin Z. Effects of aerobic exercise and resveratrol on adipocytokines in rats with nonalcoholic fatty liver disease. Sci Sports. 2023;38(1):57–67.
30.              Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol WJG. 2014;20(15):4382.
31.              Farzanegi P, Abbaszadeh H, Abbassi Daloii A, Kazemi M, Sabbaghian M, Shoeibi A, et al. Effects of aerobic exercise on histopathology and toxicology of ZnO and nano ZnO in male rats. Toxicol Environ Chem. 2018;100(1):103–14.
32.              Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci. 2019;19(7):994–1003.
33.              Darand M, Farrokhzad A, Ghavami A, Hadi A, Karimi E, Fadel A, et al. Effects of resveratrol supplementation on liver enzymes: A systematic review and meta‐analysis of randomised controlled trials. Int J Clin Pract. 2021;75(3):e13692.
34.              Bishayee A, Darvesh AS, Politis T, McGory R. Resveratrol and liver disease: from bench to bedside and community. Liver Int. 2010;30(8):1103–14.
35.              Polimeni L, Del Ben M, Baratta F, Perri L, Albanese F, Pastori D, et al. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015;7(10):1325.
36.              Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med. 2000;29(11):1106–14.
37.              Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, et al. Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis. J Clin Exp Hepatol. 2013;3(1):12–8.
38.              Toyokuni S. Oxidative stress and cancer: the role of redox regulation. Biotherapy. 1998;11(2):147–54.
39.              Hadavi S, Daneshjoo A. The effects of eight weeks of aerobic training and resveratrol supplementation on oxidative stress markers in women with metabolic syndrome. J Nutr Sci Diet. 2018;59–64.
40.              Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem. 2013;20(10):1323–31.
41.              Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore–Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092–103.
42.              Cui J, Guo Y, Yang W, Zhao X, Yu F, Tang W, et al. Effects of exercise on learning and memory, oxidative stress and nNOS expression in marginal division of striatum of ovariectomized rats. J Sports Med Phys Fitness. 2017;58(3):356–65.
43.              Gomez-Cabrera M-C, Domenech E, Viña J. Moderate exercise is an antioxidant: upregulation of antioxidant genes by  training. Free Radic Biol Med. 2008;44(2):126–31.
 
 
Journal of Nutrition,Fasting and Health
Volume 14, Issue 3
Summer 2026
Pages 203-209

  • Receive Date 09 October 2025
  • Revise Date 03 June 2026
  • Accept Date 06 June 2026